We are live on ! Find out more
TCRT icon

Alaunos Therapeutics

143 hedge funds and large institutions have $408M invested in Alaunos Therapeutics in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 52 increasing their positions, 43 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more call options, than puts

Call options by funds: $26.8M | Put options by funds: $15.1M

21% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 43

8% less funds holding

Funds holding: 156143 (-13)

20% less capital invested

Capital invested by funds: $511M → $408M (-$103M)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

39% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 31

Holders
143
Holders Change
-13
Holders Change %
-8.33%
% of All Funds
3.81%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.08%
New
19
Increased
52
Reduced
43
Closed
31
Calls
$26.8M
Puts
$15.1M
Net Calls
+$11.8M
Net Calls Change
+$13.6M
Name Holding Trade Value Shares
Change
Change in
Stake
TFCM
176
Taylor Frigon Capital Management
Arizona
-$3K -3 Closed

TCRT Hedge Fund Activity: Q1 2016 in Review

143 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2016, worth a combined $408M — down 20% from $511M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of TCRT and 19 opened new positions — a net loss of 12 holders — while 43 trimmed existing stakes and 52 added.

The largest buyer was Invesco, opening a new position worth an estimated $5.96M. The largest seller was University of Texas/Texas AM Investment Management Co (UTIMCO), exiting entirely with an estimated $20.8M sold.

  • 143 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2016, down from 156 in Q4 2015.
  • Funds reported $408M of Alaunos Therapeutics stock for Q1 2016, down 20% quarter-over-quarter.
  • 19 funds opened new Alaunos Therapeutics positions in Q1 2016 and 31 closed out, a net change of -12 holders.
  • The largest Alaunos Therapeutics buyer in Q1 2016 was Invesco, an estimated $5.96M added.
  • The largest Alaunos Therapeutics seller in Q1 2016 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $20.8M sold.

Based on aggregated 13F filings for Q1 2016.